Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Pharvaris (PHVS – Research Report). The associated price target is $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Schwartz has given his Buy rating due to a combination of factors, including Pharvaris’s progress with their RAPIDe-3 and CHAPTER-3 studies. The company has successfully achieved target enrollment in the RAPIDe-3 study, which is a significant milestone, especially in a competitive market with numerous approved and developing therapies. This swift enrollment is promising, and the anticipated topline data from the pivotal on-demand study in early 2026 further supports the potential of their lead candidate, deucrictibant, in treating hereditary angioedema.
Additionally, Schwartz highlights the ongoing enrollment in the CHAPTER-3 study, which is expected to yield topline data in the second half of 2026. Despite the presence of several approved treatment options, there remains a notable unmet need for more convenient and effective therapies, a gap that deucrictibant aims to fill. The company’s strong financial position, with a solid balance sheet and expected catalysts in the coming year, further reinforces the positive outlook. As a result, Schwartz reiterates an Outperform rating with a price target of $28.
Schwartz covers the Healthcare sector, focusing on stocks such as Insmed, Sarepta Therapeutics, and Travere Therapeutics. According to TipRanks, Schwartz has an average return of 1.2% and a 35.49% success rate on recommended stocks.
In another report released on April 7, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.